5/10
11:25 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
5/9
07:44 pm
anab
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
5/9
04:35 pm
anab
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/9
04:24 pm
anab
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) [Yahoo! Finance]
High
Report
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) [Yahoo! Finance]
5/9
04:24 pm
anab
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties [Yahoo! Finance]
High
Report
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties [Yahoo! Finance]
5/9
04:15 pm
anab
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
High
Report
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
5/9
04:10 pm
anab
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
High
Report
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
5/9
04:05 pm
anab
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
High
Report
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
5/9/2024
04:15 pm
anab
anaptysbio, inc.
MISS
Report
-12.9%
anaptysbio, inc.
3/11/2024
04:15 pm
anab
anaptysbio, inc.
BEAT
Report
11.6%
anaptysbio, inc.
5/9
04:25 pm
anab
Form 10-Q ANAPTYSBIO, INC For: Mar 31
High
Report
Form 10-Q ANAPTYSBIO, INC For: Mar 31
5/9
04:21 pm
anab
Form 8-K ANAPTYSBIO, INC For: May 09
High
Report
Form 8-K ANAPTYSBIO, INC For: May 09
5/6
01:00 pm
anab
Form SC 13G ANAPTYSBIO, INC Filed by: Frazier Life Sciences Public Fund, L.P.
Low
Report
Form SC 13G ANAPTYSBIO, INC Filed by: Frazier Life Sciences Public Fund, L.P.
4/24
04:11 pm
anab
Form ARS ANAPTYSBIO, INC For: Dec 31
Low
Report
Form ARS ANAPTYSBIO, INC For: Dec 31
4/24
04:08 pm
anab
Form DEFA14A ANAPTYSBIO, INC
Low
Report
Form DEFA14A ANAPTYSBIO, INC
4/24
04:06 pm
anab
Form DEF 14A ANAPTYSBIO, INC For: Jun 12
Low
Report
Form DEF 14A ANAPTYSBIO, INC For: Jun 12
3/26
08:11 pm
anab
Form 4 ANAPTYSBIO, INC For: Mar 22 Filed by: Faga Daniel
Low
Report
Form 4 ANAPTYSBIO, INC For: Mar 22 Filed by: Faga Daniel
3/11
04:42 pm
anab
Form S-8 ANAPTYSBIO, INC
High
Report
Form S-8 ANAPTYSBIO, INC
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
3/2
Form 10-K ANAPTYSBIO, INC For: Dec 31
18.7%
6/21
AnaptysBio Inc (NASDAQ: ANAB) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating.
11.8%
12/10
Form SC 13G/A ANAPTYSBIO, INC Filed by: FMR LLC
8.2%
10/1
Investors Yawn As Biotech Puts Up Positive Test Results — For 2 Patients [Investor's Business Daily]
8.1%
11/22
Form SC 13G ANAPTYSBIO, INC Filed by: TANG CAPITAL PARTNERS LP
7.8%
3/3
AnaptysBio Inc (NASDAQ: ANAB) had its price target lowered by analysts at SunTrust Banks, Inc. from $15.00 to $14.00. They now have a "hold" rating on the stock.
6.3%
5/1
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
5.4%
4/17
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
5.2%
4/8
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the Firm
5.2%
4/13
CLASS ACTION UPDATE for ANAB, VMW and ZM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
5.0%
8/19
Form 8-K ANAPTYSBIO, INC For: Aug 16
-13.6%
9/30
Form 8-K ANAPTYSBIO, INC For: Sep 30
-11.8%
6/24
AnaptysBio Inc (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at SunTrust Banks, Inc..
-11.4%
6/21
AnaptysBio Inc (NASDAQ: ANAB) was downgraded by analysts at Credit Suisse Group AG from an "outperform" rating to a "neutral" rating.
-8.9%
8/10
AnaptysBio Prepares for a Potential Gear Shift [The Motley Fool]
-7.8%
3/10
Form 4 ANAPTYSBIO, INC For: Mar 10 Filed by: Suria Hamza
-7.2%
2/12
Form SC 13G/A ANAPTYSBIO, INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-7.0%
9/25
Form 8-K ANAPTYSBIO, INC For: Sep 24
-6.8%
3/31
ANAPTYSBIO SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AnaptysBio, Inc. - ANAB
-5.9%
3/27
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm
-5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register